Skip to main content

Advertisement

SpringerLink
Log in

Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

This study used a simulation model to determine the cost-effective threshold of fracture risk to treat osteoporosis among elderly Chinese women. Osteoporosis treatment is cost-effective among average-risk women who are at least 75 years old and above-average-risk women who are younger than 75 years old.

Introduction

Aging of the Chinese population is imposing increasing economic burden of osteoporosis. This study evaluated the cost-effectiveness of osteoporosis treatment among the senior Chinese women population.

Methods

A discrete event simulation model using age-specific probabilities of hip fracture, clinical vertebral fracture, wrist fracture, humerus fracture, and other fracture; costs (2015 US dollars); and quality-adjusted life years (QALYs) was used to assess the cost-effectiveness of osteoporosis treatment. Incremental cost-effectiveness ratio (ICER) was calculated. The willingness to pay (WTP) for a QALY in China was compared with the calculated ICER to decide the cost-effectiveness. To determine the absolute 10-year hip fracture probability at which the osteoporosis treatment became cost-effective, average age-specific probabilities for all fractures were multiplied by a relative risk (RR) that was systematically varied from 0 to 10 until the WTP threshold was observed for treatment relative to no intervention. Sensitivity analyses were also performed to evaluate the impacts from WTP and annual treatment costs.

Results

In baseline analysis, simulated ICERs were higher than the WTP threshold among Chinese women younger than 75, but much lower than the WTP among the older population. Sensitivity analyses indicated that cost-effectiveness could vary due to a higher WTP threshold or a lower annual treatment cost. A 30 % increase in WTP or a 30 % reduction in annual treatment costs will make osteoporosis treatment cost-effective for Chinese women population from 55 to 85.

Conclusions

The current study provides evidence that osteoporosis treatment is cost-effective among a subpopulation of Chinese senior women. The results also indicate that the cost-effectiveness of using osteoporosis treatment is sensitive to the WTP threshold and annual treatment costs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N (2005) Assessment of fracture risk. Osteoporos Int 16:581–589

    Article  PubMed  Google Scholar 

  2. Kanis JA, Black D, Cooper C, et al. (2002) A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 13:527–536

    Article  CAS  PubMed  Google Scholar 

  3. 1998) Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction. Osteoporos Int 8(Suppl 4):S7–80

  4. Jiang Y, Ni W (2015) Expected lifetime numbers, risks, and burden of osteoporotic fractures for 50-year old Chinese women: a discrete event simulation incorporating FRAX. J Bone Miner Metab

  5. Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936

    Article  PubMed  Google Scholar 

  6. Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767

    Article  PubMed  Google Scholar 

  7. Liang H, ZHONG W, Ning L (2009) Statistics on the expenses for medical care of osteoporotic fractures in Beijing Jishuitan Hospital (from 2000 to 2006)[J]. Journal of Practical Orthopaedics 5:000

    Google Scholar 

  8. Mithal A, Ebeling P, Kyer C (2013) The Asia-Pacific regional audit: epidemiology, costs, and burden of osteoporosis in 2013. International osteoporosis foundation

  9. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468–473

    Article  CAS  PubMed  Google Scholar 

  10. Hasegawa Y, Suzuki S, Wingstrand H (2007) Risk of mortality following hip fracture in Japan. J Orthop Sci 12:113–117

    Article  PubMed  Google Scholar 

  11. Lips P, van Schoor NM (2005) Quality of life in patients with osteoporosis. Osteoporos Int 16:447–455

    Article  PubMed  Google Scholar 

  12. Jansen JP, Bergman GJ, Huels J, Olson M (2011) The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum 40(275–284):e271–e272

    Google Scholar 

  13. Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. PharmacoEconomics 21:305–314

    Article  PubMed  Google Scholar 

  14. Strom O, Borgstrom F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries—an economic evaluation based on the fracture intervention trial. Osteoporos Int 18:1047–1061

    Article  CAS  PubMed  Google Scholar 

  15. Zhang Z, Ou Y, Sheng Z, Liao E (2014) How to decide intervention thresholds based on FRAX in central south Chinese postmenopausal women. Endocrine 45:195–197

    Article  CAS  PubMed  Google Scholar 

  16. Bleibler F, Rapp K, Jaensch A, Becker C, Konig H-H (2014) Expected lifetime numbers and costs of fractures in postmenopausal women with and without osteoporosis in Germany: a discrete event simulation model. BMC Health Serv Res 14:284

    Article  PubMed  PubMed Central  Google Scholar 

  17. Caro JJ (2005) Pharmacoeconomic analyses using discrete event simulation. PharmacoEconomics 23:323–332

    Article  PubMed  Google Scholar 

  18. Kung AW, Lee KK, Ho AY, Tang G, Luk KD (2007) Ten-year risk of osteoporotic fractures in postmenopausal Chinese women according to clinical risk factors and BMD T-scores: a prospective study. J Bone Miner Res 22:1080–1087

    Article  PubMed  Google Scholar 

  19. Hiligsmann M, Ethgen O, Bruyère O, Richy F, Gathon HJ, Reginster JY (2009) Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 12:687–696

    Article  PubMed  Google Scholar 

  20. Borgström F (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21:495–505

    Article  PubMed  Google Scholar 

  21. Borgström F, Ström O, Kleman M, McCloskey E, Johansson H, Odén A, Kanis J (2011) Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective. Osteoporos Int 22:955–965

    Article  PubMed  Google Scholar 

  22. Kim K, Svedbom A, Luo X, Sutradhar S, Kanis J (2014) Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm. Osteoporos Int 25:325–337

    Article  CAS  PubMed  Google Scholar 

  23. Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA, Manitoba Bone Density P (2012) Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Miner Res 27:1243–1251

    Article  CAS  PubMed  Google Scholar 

  24. Liao E-Y, Wu X-P, Deng X-G, Huang G, Zhu X-P, Long Z-F, Wang W-B, Tang W-L, Zhang H (2002) Age-related bone mineral density, accumulated bone loss rate and prevalence of osteoporosis at multiple skeletal sites in Chinese women. Osteoporos Int 13:669–676

    Article  PubMed  Google Scholar 

  25. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP (1982) A convenient approximation of life expectancy (the “DEALE”): II. Use in medical decision-making The American journal of medicine 73:889–897

    CAS  PubMed  Google Scholar 

  26. Fang X, Shi J, Song X, Mitnitski A, Tang Z, Wang C, Yu P, Rockwood K (2012) Frailty in relation to the risk of falls, fractures, and mortality in older Chinese adults: results from the Beijing Longitudinal Study of Aging. J Nutr Health Aging 16:903–907

    Article  CAS  PubMed  Google Scholar 

  27. (2012) Life tables by country China. http://apps.who.int/gho/data/?theme=main&vid=60340 Accessed Mar 24 2015

  28. Wang C-B, Lin C-FJ, Liang W-M, Cheng C-F, Chang Y-J, Wu H-C, Wu T-N, Leu T-H (2013) Excess mortality after hip fracture among the elderly in Taiwan: a nationwide population-based cohort study. Bone 56:147–153

    Article  PubMed  Google Scholar 

  29. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15:108–112

    Article  PubMed  Google Scholar 

  30. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513–521

    Article  CAS  PubMed  Google Scholar 

  31. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL, National Osteoporosis Foundation Guide C (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Hwang JS, Chin LS, Chen JF, Yang TS, Chen PQ, Tsai KS, Leung PC (2011) The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis. J Bone Miner Metab 29:328–333

    Article  CAS  PubMed  Google Scholar 

  33. Sun S, Chen J, Johannesson M, Kind P, Xu L, Zhang Y, Burström K (2011) Population health status in China: EQ-5D results, by age, sex and socio-economic status, from the National Health Services Survey 2008. Qual Life Res 20:309–320

    Article  PubMed  Google Scholar 

  34. http://db.yaozh.com/yaopinjiage?name=%E5%94%91%E6%9D%A5%E8%86%A6%E9%85%B8&wenjianhao=&jixing=&yearsecendstr=&yearsecendend=&guige=&firstjiage=%E5%85%A8%E9%83%A8&shengchanqiye=. Accessed May 17 2016

  35. Qu B, Ma Y, Yan M, Wu H-H, Fan L, Liao D-F, Pan X-M, Hong Z (2014) The economic burden of fracture patients with osteoporosis in western China. Osteoporos Int 25:1853–1860

    Article  CAS  PubMed  Google Scholar 

  36. Shih V, Chan A, Xie F, Ko Y (2012) Health state utility assessment for breast cancer. Value in Health Regional Issues 1:93–97

    Article  Google Scholar 

  37. Hagino H, Nakamura T, Fujiwara S, Oeki M, Okano T, Teshima R (2009) Sequential change in quality of life for patients with incident clinical fractures: a prospective study. Osteoporos Int 20:695–702

    Article  CAS  PubMed  Google Scholar 

  38. (2015) Consumer Price Index: All Items for China©. http://research.stlouisfed.org/fred2/series/CHNCPIALLMINMEI Accessed Mar 25 2015

  39. (2015) US Dollar to Chinese Yuan Renminbi Chart. http://www.xe.com/currencycharts/?from=USD&to=CNY&view=1Y Accessed Mar 12 2015

  40. (2015) GDP per capita (current US$). http://data.worldbank.org/indicator/NY.GDP.PCAP.CD Accessed Mar 24 2015

  41. Zhao F-L, Yue M, Yang H, Wang T, Wu J-H, Li S-C (2011) Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis. Med Care 49:267–272

    Article  PubMed  Google Scholar 

  42. Moriwaki K, Komaba H, Noto S, Yanagisawa S, Takiguchi T, Inoue H, Toujo T, Fukagawa M, Takahashi HE (2013) Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan. J Bone Miner Res 28:395–403

    Article  PubMed  Google Scholar 

  43. Kling JM, Clarke BL, Sandhu NP (2014) Osteoporosis prevention, screening, and treatment: a review. J Women’s Health (Larchmt) 23:563–572

    Article  Google Scholar 

  44. Kanis JA, Johnell O, Oden A, Borgstrom F, Johansson H, De Laet C, Jonsson B (2005) Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int 16:6–14

    Article  PubMed  Google Scholar 

  45. Caro JJ, Möller J, Getsios D (2010) Discrete event simulation: the preferred technique for health economic evaluations? Value Health 13:1056–1060

    Article  PubMed  Google Scholar 

  46. Van Gestel A, Severens JL, Webers CA, Beckers HJ, Jansonius NM, Schouten JS (2010) Modeling complex treatment strategies: construction and validation of a discrete event simulation model for glaucoma. Value Health 13:358–367

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical and Health Economics, School of Pharmacy, University of Southern California, 635 Downey Way, VPD Suite 210, Los Angeles, CA, 90089-3333, USA

    W. Ni & Y. Jiang

Authors
  1. W. Ni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y. Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y. Jiang.

Ethics declarations

Conflicts of interest

None.

Electronic supplementary material

ESM 1

(PDF 130 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ni, W., Jiang, Y. Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model. Osteoporos Int 28, 529–538 (2017). https://doi.org/10.1007/s00198-016-3751-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-016-3751-z

Keywords

Search

Navigation